Abstract
Abstract Background Remote patient monitoring via web applications has been reported to have benefits with improvement in patient-reported quality of life, medication adherence, and decreased heath care costs. Mobile applications can be used for symptom reporting and this along with home biomarker testing can facilitate patient initiated follow up. There remain uncertainties in the acceptance of digital technologies in routine follow up care among IBD patients. We aimed to survey the pilot users of MyIBD care app and CalproSmart home calprotectin monitoring in an IBD cohort Methods Patients participating in the patient initiated follow up (PIFU) cohort in IBD Home digital care pathway at a tertiary IBD referral centre were included in this pilot survey before full roll out of the programme. Patients were given detailed written and electronic information about the pathway before signing up. Predefined survey questions were administered using electronic in app methodology. The survey questions were ranked in Likert scale from strongly agree, agree, neither agree or disagree, disagree and strongly disagree. Data reported as proportion of responses to each category. Results 132 surveys were collected and analysed. Ninety three percent of responses understood the rationale for their inclusion to the digital pathway. Confidence in contacting the IBD team through digital pathway was reported in 89% of responses and 68% felt more in control of own condition. Eight six percent of patients understood the requirements for completing patient reported outcome measures and home calprotectin test while in the pathway and also felt confident in taking home calprotectin test. However only 44% felt closer to the clinical care team with the pathway. Conclusion Digital pathway incorporating a patient initiated follow up and self-monitoring is acceptable to IBD patients in stable remission with high satisfaction scores in all domains
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.